We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
Read MoreHide Full Article
Pediatrix Medical Group, Inc. (MD - Free Report) is strategically positioned to grow on the back of delivering high-quality, evidence-based care in the healthcare space. The company has gained 5.6% in the year-to-date (YTD) period, outperforming the industry average of a 6.4% fall.
Pediatrix Medical — with a market cap of $1.2 billion — is a physician services provider company headquartered in Sunrise, FL. It provides newborn, maternal-fetal, radiology, pediatric cardiology and other pediatric subspecialties physician services in the United States and Puerto Rico. It also offers neonatal care services to babies born prematurely or with complications. Its forward P/E ratio of 8.72 is lower than the industry average of 13.87.
Due to its solid prospects, Pediatrix Medical currently carries a Zacks Rank #2 (Buy)
Where Do Estimates for MD Stand?
The Zacks Consensus Estimate for Pediatrix Medical’s 2025 earnings is pegged at $1.56 per share, indicating a 3.3% year-over-year rise. In the past month, it has witnessed two upward estimate revisions against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $1.9 billion for 2025. It comfortably beat earnings estimates in each of the past four quarters, with an average surprise of 24.6%.
Pediatrix Medical Group, Inc. Price and EPS Surprise
Pediatrix Medical’s growth is being supported by strong same-unit revenue growth, improved payor mix and growth in hospital contract administrative fees.
Same-unit revenues improved 6.2% year over year in the first quarter of 2025, beating the Zacks Consensus Estimate by 0.7%. Solid performance in its hospital-based services, rise in NICU days, steady growth in maternal-fetal medicine and ongoing benefits from favorable reimbursement trends will support its performance.
MD has recently entered into agreements to take over operations of multiple NICU, MFM and OB hospitals, which will now be integrated into a broader hospital system portfolio.
MD increased its projection for adjusted EBITDA from the range of $215 million-$235 million to the $220 million-$240 million band in 2025. Pediatrix Medical’s total operating expenses declined 11% year over year to $426.3 million in the first quarter of 2025. Our model suggests this metric could decline by nearly 17.8% year over year in 2025, thanks to lower practice salaries and benefits, practice supplies and other operating expenses.
In the first quarter of 2025, the company bought back common shares worth $1.6 million. As of March 31, 2025, $1.3 million remained authorized for repurchase.
MD: Risks to Watch
However, there are some factors that investors should keep a careful eye on.
Pediatrix Medical has been grappling with a significant debt level over the past several years. As of March 31, 2025, it had a net debt of $612.6 million, significantly higher than the cash balance of $99 million. This is likely to put pressure on MD’s interest expenses. Its long-term debt to capital is 42.8%, higher than the industry’s average of 40.5%. Also, the company has faced challenges in its free cash flow generation over the past five years, experiencing a decline on three occasions. First-quarter 2025 free cash flow was in the negative zone.
Final Verdict: Buy MD Stock Now
Pediatrix Medical presents a compelling investment opportunity, backed by consistent earnings surprises, strategic acquisitions and a focus on high-quality, specialized care. With improving operating margins, upward earnings revisions and lower valuation, the company is well-positioned for continued success. For investors seeking value and stability in the healthcare sector, MD offers a solid case for inclusion.
The Zacks Consensus Estimate for Clover Health Investments’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. Clover Health Investments beat earnings estimates in each of the trailing four quarters, with the average surprise being 114.6%. The consensus estimate for current-year revenues is pegged at $1.9 billion, suggesting 37.7% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of $1.09 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. GeneDx Holdings beat earnings estimates in each of the trailing four quarters, with the average surprise being 145.8%. The consensus estimate for current-year revenues is pegged at $374.1 billion, suggesting 22.5% year-over-year growth.
The Zacks Consensus Estimate for Integer Holdings’ current-year earnings of $6.33 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. Integer Holdings beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 2.8%. The consensus estimate for current-year revenues is pegged at $1.9 billion, suggesting 7.7% year-over-year growth.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Here's Why You Should Add Pediatrix Medical to Your Portfolio Now
Pediatrix Medical Group, Inc. (MD - Free Report) is strategically positioned to grow on the back of delivering high-quality, evidence-based care in the healthcare space. The company has gained 5.6% in the year-to-date (YTD) period, outperforming the industry average of a 6.4% fall.
Pediatrix Medical — with a market cap of $1.2 billion — is a physician services provider company headquartered in Sunrise, FL. It provides newborn, maternal-fetal, radiology, pediatric cardiology and other pediatric subspecialties physician services in the United States and Puerto Rico. It also offers neonatal care services to babies born prematurely or with complications. Its forward P/E ratio of 8.72 is lower than the industry average of 13.87.
Due to its solid prospects, Pediatrix Medical currently carries a Zacks Rank #2 (Buy)
Where Do Estimates for MD Stand?
The Zacks Consensus Estimate for Pediatrix Medical’s 2025 earnings is pegged at $1.56 per share, indicating a 3.3% year-over-year rise. In the past month, it has witnessed two upward estimate revisions against none in the opposite direction. Furthermore, the consensus mark for revenues is pegged at $1.9 billion for 2025. It comfortably beat earnings estimates in each of the past four quarters, with an average surprise of 24.6%.
Pediatrix Medical Group, Inc. Price and EPS Surprise
Pediatrix Medical Group, Inc. price-eps-surprise | Pediatrix Medical Group, Inc. Quote
MD’s Growth Drivers
Pediatrix Medical’s growth is being supported by strong same-unit revenue growth, improved payor mix and growth in hospital contract administrative fees.
Same-unit revenues improved 6.2% year over year in the first quarter of 2025, beating the Zacks Consensus Estimate by 0.7%. Solid performance in its hospital-based services, rise in NICU days, steady growth in maternal-fetal medicine and ongoing benefits from favorable reimbursement trends will support its performance.
MD has recently entered into agreements to take over operations of multiple NICU, MFM and OB hospitals, which will now be integrated into a broader hospital system portfolio.
MD increased its projection for adjusted EBITDA from the range of $215 million-$235 million to the $220 million-$240 million band in 2025. Pediatrix Medical’s total operating expenses declined 11% year over year to $426.3 million in the first quarter of 2025. Our model suggests this metric could decline by nearly 17.8% year over year in 2025, thanks to lower practice salaries and benefits, practice supplies and other operating expenses.
In the first quarter of 2025, the company bought back common shares worth $1.6 million. As of March 31, 2025, $1.3 million remained authorized for repurchase.
MD: Risks to Watch
However, there are some factors that investors should keep a careful eye on.
Pediatrix Medical has been grappling with a significant debt level over the past several years. As of March 31, 2025, it had a net debt of $612.6 million, significantly higher than the cash balance of $99 million. This is likely to put pressure on MD’s interest expenses. Its long-term debt to capital is 42.8%, higher than the industry’s average of 40.5%. Also, the company has faced challenges in its free cash flow generation over the past five years, experiencing a decline on three occasions. First-quarter 2025 free cash flow was in the negative zone.
Final Verdict: Buy MD Stock Now
Pediatrix Medical presents a compelling investment opportunity, backed by consistent earnings surprises, strategic acquisitions and a focus on high-quality, specialized care. With improving operating margins, upward earnings revisions and lower valuation, the company is well-positioned for continued success. For investors seeking value and stability in the healthcare sector, MD offers a solid case for inclusion.
Other Stocks to Consider
Some other top-ranked stocks in the Medical space are Clover Health Investments Corp (CLOV - Free Report) , GeneDx Holdings Corp (WGS - Free Report) and Integer Holdings Corporation (ITGR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Clover Health Investments’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. Clover Health Investments beat earnings estimates in each of the trailing four quarters, with the average surprise being 114.6%. The consensus estimate for current-year revenues is pegged at $1.9 billion, suggesting 37.7% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of $1.09 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. GeneDx Holdings beat earnings estimates in each of the trailing four quarters, with the average surprise being 145.8%. The consensus estimate for current-year revenues is pegged at $374.1 billion, suggesting 22.5% year-over-year growth.
The Zacks Consensus Estimate for Integer Holdings’ current-year earnings of $6.33 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. Integer Holdings beat earnings estimates in three of the trailing four quarters and missed once, with the average surprise being 2.8%. The consensus estimate for current-year revenues is pegged at $1.9 billion, suggesting 7.7% year-over-year growth.